Table 2.
Council to Advance Human Health (CAHH) funded projects and outcomes including company formed, clinical trials, and Pharma partnerships
| Date | CAHH programs | Company formed | IP licensed | Clinical trials | Follow on Pharma partner |
|---|---|---|---|---|---|
| 2012 | Alzheimer’s disease therapeutic | ReXceptor* | 2013 | Ph1 2013 | |
| 2012 | Metastasis detection and prognosis | NeoIndicate | 2020 | ||
| 2012 | Small molecules for triple (-) breast cancer | ||||
| 2012 | Photodynamic therapy for skin disease | Fluence Therapeutics* | |||
| 2013 | Protein tyrosine phosphatase (PTP)-sigma peptide for tissue regeneration | NervGen | 2018 | Ph1 2021 | |
| 2014 | Remyelination therapeutics for Multiple Sclerosis | Convelo Therapeutics | 2017 | Genentech (2019) | |
| 2014 | Anti-virulence agent against methicillin-resistant Staphylococcus aureus (MRSA) | Q2 Pharma | 2017 | ||
| 2014 | 15-Hydroxyprostaglandin Dehydrogenase (PGDH) inhibitor for tissue regeneration | Rodeo Therapeutics | 2017 | Amgen (2021) | |
| 2015 | Small molecule for inflammation | ||||
| 2015 | Ribonucleotide Reductase modulators for pancreatic cancer treatment | ||||
| 2015 | Apoptosis regulator for cancer treatment | ||||
| 2016 | Virus nanoparticles for cancer immunotherapy | Mosaic Immunoengineering | 2020 | ||
| 2016 | Peptide and small molecule inhibitors of Huntingdon’s disease | ||||
| 2017 | Synthetic platelets for hemorrhage | Haima Therapeutics | 2020 | ||
| 2017 | Phosphatases in tumorigenesis | ||||
| 2018 | tRNA suppression to treat Dravet and other epilepsies | Tevard Biosciences | 2019 | Zogenix (2020) | |
| 2018 | Gene therapy treatment for haplo-insufficiency diseases | ||||
| 2019 | Osteosarcoma immunotherapy | ||||
| 2019 | Myeloid-related protein 14 (MRP14) antibody for Lupus | ||||
| 2020 | B-cell activating factor chimeric antigen receptor Natural Killer (BAFF CAR-NK) cells to treat B-cell cancers |
*
Licensed prior to CAHH award support.